Replies to post #275632 on Amarin Corp Plc (AMRN)

[ggwpq]

flubber, thanks for the article. Regarding Graham #2:

(2) Ascertain the differences between the claimed invention and the prior art;

For our case, the difference is TG population. After reading this, https://drive.google.com/drive/folders/1W5Z3OnsQqyEqAlGTuiYF17jIapWGCLf1, do you think the generics took up the burden to explain why the two TG population should behave the same as far as LDL-C is concerned? Or did Du put the burden on Amarin despite there is an easy to understand explanation, i.e., Friedewald Equation:

LDL = TC(total cholesterol)- HDL-C(high density lipoprotein cholesterol) -Trigs/5

For SHTG (TG>500), a POSA should expect TG reduction to be above 30% for using DHA/EPA
For HTG, a POSA should know the TG reduction is about 10-20% for using DHA/EPA

Therefore, the greater the %TG reduction, i.e. SHTG population, a POSA should expect a greater rise in LDL-C. So a POSA looking at Mori and saw EPA raised LDL-C for even a marginally above average TG population, he should stay as far away from EPA as possible for SHTG population. That's why experts said increased LDL-C was inevitable for SHTG lowering therapy and that's why there was such a long unmet need after Mori until the discovery of Vascepa. Only hindsight could force Mori to be a valid prior art.